April 14, 2008 - Pharmalink AB, a specialty pharma company, announces today that the U.S. Patent and Trademark Office has approved U.S. Patent No. 7,351,427, relating to the pharmaceutical composition, method of preparation and method of treatment by use of busulfan, which is the active agent in Pharmalink's Busulipo(tm). Busulfan is a well-established chemotherapy agent used for myeloablation (severe suppression of bone marrow activity) as a preconditioning regimen to bone marrow stem cell transplantation, for example, in the treatment of leukaemia. The patent application was filed in the U.S. in 2003 and will expire in 2020 (term adjusted).
April 14, 2008- Starpharma Holdings Ltd has filed a patent application for the use of SPL7013, the active ingredient in VivaGel, to inhibit hyaluronidase activity in the treatment or prevention of a number of diseases.
April 14, 2008 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited announced today that it had presented new data on its patented PG500 series of compounds at the annual American Association for Cancer Research (AACR) meeting being held in San Diego. The meeting brings together approximately 17,000 participants from around the world to discuss new and significant advances in the knowledge surrounding the causes, diagnosis, treatment and prevention of cancer.
Genta Incorporated today announced that the Company has received notice that its patent application covering novel pharmaceutical gallium compositions and complexes has been allowed by the U.S. Patent Office.
No comments:
Post a Comment